RheoSwitch Therapeutic System (RTS)

The RheoSwitch Therapeutic System (RTS) is a synthetic, ligand-inducible gene switch platform developed for controlled, localized expression of therapeutic genes in mammalian cells. It consists of two engineered transcription factors (derived from insect and human/nuclear receptor components), an inducible promoter, and a small-molecule ligand (typically veledimex) that provides precise, reversible, and titratable control over target gene expression. In the absence of the ligand, the system remains “off.” Upon ligand administration, the complex heterodimerizes, binds DNA, and activates transcription of the engineered gene. RTS has been clinically validated, especially in protocols aiming to express IL-12 for local immune stimulation in cancer therapy, enabling tumor-selective cytokine production with manageable toxicity profiles. It represents an advanced synthetic biology approach rather than a conventional biological target.

Other names

RTS systemRheoSwitchRheoSwitch gene switchRheoSwitch Therapeutic System®

Provides ligand-inducible transcriptional activation of a therapeutic gene via engineered fusion proteins (derived from the ecdysone receptor and retinoid X receptor domains) that form an active transcription factor complex only in the presence of the small-molecule ligand (veledimex). Enables “on/off” control of transgene expression, with tight regulation and dose-responsiveness determined by the ligand. Used to enable localized, controllable cytokine production in clinical gene therapy protocols.